

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Ribociclib (Kisqali) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Ribociclib (Kisqali).** <u>Please complete all sections, incomplete forms will delay processing.</u> <u>Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104</u>. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.**

KP-MAS Formulary can be found at: http://www.providers.kaiserpermanente.org/mas/formulary.html
Covered Indications:

Breast Cancer

1 - Patient Information			
Patient Name:	Kaiser Medical ID#:	Date of Birth:	
2 – Prescriber Information			
Prescriber Name:	Specialty:	NPI:	
Prescriber Address:			
Prescriber Phone #:	Prescriber Fax #:		
3 – Pharmacy Information			
Pharmacy Name:	Pharmacy NPI:		
Pharmacy Phone #	Pharmacy Fax #:		
4 – Drug Therapy Requested			
	·		
Drug 2: Name/Strength/Formulation:	:		
5– Diagnosis/Clinical Criteria			
 Is this request for initial or contin Initial therapy Indicate the patient's diagnosis for 	□ Continuing therapy, State date:		

 Is the treatment for recurrent or metastatic ER/PR+, HER2- brointolerance to palbociclib (but have not experienced cancer properties). No Yes 	·
For continuation of therapy, please respond to additional questions	below.
 Does the member show evidence of progressive disease while □ No □ Yes 	
6 – Prescriber Sign	-Off
Additional Information – Please submit chart notes/medical records no to any of the above questions, please provide any additional suppronsideration:	• • • • • • • • • • • • • • • • • • • •
I certify that the information provided is accurate. Supporting	g documentation is available for State audits.
Prescriber Signature:	Date:
Please Note: This document contains confidential information, including protected health inform	ation, intended for a specific individual and purpose. The information is

private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility

Breast Cancer: